-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 QeQOmXgEj6okmdz2CIdGuWjilUwT8+VLJq13bF3fhgtgWvZmaLwv2Z9HjKmF8Cua
 h0aQEEjeSCLM934xlC/SlQ==

<SEC-DOCUMENT>0000012208-06-000023.txt : 20061102
<SEC-HEADER>0000012208-06-000023.hdr.sgml : 20061102
<ACCEPTANCE-DATETIME>20061102170118
ACCESSION NUMBER:		0000012208-06-000023
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20060930
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20061102
DATE AS OF CHANGE:		20061102

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIO RAD LABORATORIES INC
		CENTRAL INDEX KEY:			0000012208
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				941381833
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-07928
		FILM NUMBER:		061183490

	BUSINESS ADDRESS:	
		STREET 1:		1000 ALFRED NOBEL DR
		CITY:			HERCULES
		STATE:			CA
		ZIP:			94547
		BUSINESS PHONE:		5107247000
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8kcover093006.htm
<TEXT>
<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>
<HEAD>
<TITLE>Bio-Rad Laboratories, Inc</TITLE>
<META NAME="author" CONTENT="Stephanie Trudrung">
<META NAME="date" CONTENT="11/02/2006">
</HEAD>
<BODY style="line-height:12pt; font-family:Times New Roman; font-size:10pt; color:#000000">
<DIV style="width:468pt"><P style="margin:0pt"><BR></P>
<TABLE style="font-size:10pt" cellspacing=0><TR><TD width=468></TD></TR>
<TR><TD valign=top width=624><P style="line-height:13pt; margin:0pt; font-size:11pt" align=center>UNITED STATES</P>
<P style="line-height:13pt; margin:0pt; font-size:11pt" align=center>SECURITIES AND EXCHANGE COMMISSION</P>
<P style="line-height:13pt; margin:0pt; font-size:11pt" align=center>Washington, D.C. &nbsp;20549</P>
<P style="margin:0pt" align=center><BR></P>
<P style="line-height:13pt; margin:0pt; font-size:11pt" align=center>Form 8-K</P>
<P style="margin:0pt" align=center><BR></P>
<P style="line-height:13pt; margin:0pt; font-size:11pt" align=center>CURRENT REPORT</P>
<P style="line-height:13pt; margin:0pt; font-size:11pt" align=center>PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</P>
</TD></TR>
<TR><TD valign=top width=624><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD style="border-bottom:0.5pt solid #000000" valign=top width=624><P style="line-height:13pt; margin:0pt; font-size:11pt" align=center>Date of Report<FONT FACE="Symbol">:</FONT> &nbsp;November 2, 2006</P>
</TD></TR>
<TR><TD valign=top width=624><P style="line-height:13pt; margin:0pt; font-size:11pt" align=center>(Date of earliest event reported)</P>
</TD></TR>
</TABLE>
<P style="margin:0pt" align=center><BR></P>
<TABLE style="font-size:10pt" cellspacing=0><TR><TD width=36></TD><TD width=432></TD></TR>
<TR><TD valign=top width=48><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=576><P style="line-height:13pt; margin:0pt; font-size:11pt" align=center>BIO-RAD LABORATORIES, INC.</P>
</TD></TR>
</TABLE>
<P style="line-height:13pt; margin:0pt; padding-left:36pt; font-size:11pt" align=center>(Exact name of registrant as specified in its charter)</P>
<P style="margin:0pt" align=center><BR></P>
<P style="line-height:13pt; margin:0pt; padding-left:14.4pt; font-size:11pt" align=center>Commission file number <U>1-7928</U></P>
<P style="margin:0pt" align=center><BR></P>
<TABLE style="font-size:10pt" cellspacing=0><TR><TD width=262.75></TD><TD width=13.15></TD><TD width=14.4></TD><TD width=177.7></TD></TR>
<TR><TD style="border-bottom:0.5pt solid #000000" valign=top width=350.333><P style="line-height:13pt; margin:0pt; font-size:11pt" align=center>Delaware</P>
</TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=17.533><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=256.133 colspan=2><P style="margin:0pt; font-size:11pt" align=center>94-1381833</P>
</TD></TR>
<TR><TD valign=top width=350.333><P style="margin:0pt; font-size:11pt" align=center>(State or other jurisdiction of incorporation or organization)</P>
</TD><TD valign=top width=17.533><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=256.133 colspan=2><P style="margin:0pt; font-size:11pt" align=center>(I.R.S. Employer Identification No.)</P>
</TD></TR>
<TR><TD valign=top width=350.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=17.533><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=256.133 colspan=2><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD style="border-bottom:0.5pt solid #000000" valign=top width=350.333><P style="margin:0pt; font-size:11pt" align=center>1000 Alfred Nobel Drive, Hercules, California</P>
</TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=17.533><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=256.133 colspan=2><P style="margin:0pt; font-size:11pt" align=center>94547</P>
</TD></TR>
<TR><TD valign=top width=367.867 colspan=2><P style="margin:0pt; font-size:11pt" align=center>(Address of principal executive offices)</P>
</TD><TD valign=top width=19.2><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=236.933><P style="margin:0pt; font-size:11pt" align=center>(Zip Code)</P>
</TD></TR>
<TR><TD valign=top width=624 colspan=4><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD style="border-bottom:0.5pt solid #000000" valign=top width=624 colspan=4><P style="margin:0pt; font-size:11pt" align=center>(510) 724-7000</P>
</TD></TR>
<TR><TD valign=top width=624 colspan=4><P style="margin:0pt; font-size:11pt" align=center>Registrant's telephone number, including area code</P>
</TD></TR>
<TR><TD valign=top width=624 colspan=4><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=624 colspan=4><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=624 colspan=4><P style="line-height:14pt; margin-top:0pt; margin-bottom:-14pt; font-size:11pt">ITEM 2.02.</P>
<P style="margin:0pt; text-indent:72pt; font-size:11pt">RESULTS OF OPERATIONS AND FINANCIAL CONDITION.</P>
</TD></TR>
<TR><TD valign=top width=624 colspan=4><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=624 colspan=4><P style="margin:0pt; font-size:11pt">The information in Item 2.02 of the Report, including Exhibit 99.1 attached hereto, is being furnished</P>
</TD></TR>
<TR><TD valign=top width=624 colspan=4><P style="margin:0pt; font-size:11pt">pursuant to Item 2.02 of Form 8-K. &nbsp;Consequently, it is not deemed &#147;filed&#148; for the purposes of Section 18</P>
</TD></TR>
<TR><TD valign=top width=624 colspan=4><P style="margin:0pt; font-size:11pt">of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that </P>
</TD></TR>
<TR><TD valign=top width=624 colspan=4><P style="margin:0pt; font-size:11pt">section. &nbsp;It may only be incorporated by reference in another filing under the Exchange Act or</P>
</TD></TR>
<TR><TD valign=top width=624 colspan=4><P style="margin:0pt; font-size:11pt">Securities Act of 1933, as amended, if such subsequent filing specifically references this Form 8-K.</P>
</TD></TR>
<TR><TD valign=top width=624 colspan=4><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=624 colspan=4><P style="margin:0pt; font-size:11pt">On November 2, 2006, Bio-Rad Laboratories, Inc. announced its results of operations and financial</P>
</TD></TR>
<TR><TD valign=top width=624 colspan=4><P style="margin:0pt; font-size:11pt">condition as of and for the quarter ended September 30, 2006. &nbsp;A copy of the press release is attached</P>
</TD></TR>
<TR><TD valign=top width=624 colspan=4><P style="margin:0pt; font-size:11pt">hereto as Exhibit 99.1 and is incorporated herein by reference.</P>
</TD></TR>
<TR><TD valign=top width=624 colspan=4><P style="font-size:2pt">&nbsp;</P></TD></TR>
</TABLE>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR>
<BR></P>
<P style="margin:0pt; page-break-before:always"><BR></P>
<P style="margin:0pt"><BR></P>
<TABLE style="font-size:10pt" cellspacing=0><TR><TD width=63></TD><TD width=396></TD></TR>
<TR><TD valign=top width=612 colspan=2><P style="line-height:13pt; margin-top:0pt; margin-bottom:-13pt; font-size:11pt">Item 9.01</P>
<P style="line-height:13pt; margin:0pt; text-indent:72pt; font-size:11pt">FINANCIAL STATEMENTS AND EXHIBITS</P>
</TD></TR>
<TR><TD valign=top width=84><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=528><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=84><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=528><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=84><P style="line-height:13pt; margin:0pt; font-family:Symbol; font-size:11pt"><FONT FACE="Symbol">(</FONT><FONT FACE="Times New Roman">c</FONT>)</P>
</TD><TD valign=top width=528><P style="line-height:13pt; margin:0pt; font-size:11pt"><FONT FACE="Times New Roman">Exhibits</FONT></P>
</TD></TR>
<TR><TD valign=top width=84><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=528><P style="font-size:2pt">&nbsp;</P></TD></TR>
</TABLE>
<P style="margin:0pt"><BR></P>
<TABLE style="font-size:10pt" cellspacing=0><TR><TD width=63></TD><TD width=11.8></TD><TD width=384.2></TD></TR>
<TR><TD valign=top width=84><P style="line-height:13pt; margin:0pt; font-size:11pt">Exhibit </P>
</TD><TD valign=top width=15.733><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=512.267><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD style="border-bottom:0.5pt solid #000000" valign=top width=84><P style="line-height:13pt; margin:0pt; font-size:11pt">Number</P>
</TD><TD valign=top width=15.733><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=512.267><P style="line-height:13pt; margin:0pt; font-size:11pt">Description</P>
</TD></TR>
<TR><TD valign=top width=84><P style="line-height:13pt; margin:0pt; font-size:11pt">99.1</P>
</TD><TD valign=top width=15.733><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=512.267><P style="line-height:13pt; margin:0pt; font-size:11pt">Press Release for third quarter 2006 financial results of</P>
</TD></TR>
<TR><TD valign=top width=84><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=15.733><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=512.267><P style="line-height:13pt; margin:0pt; font-size:11pt">Bio-Rad Laboratories, Inc., dated November 2, 2006. &nbsp;This exhibit is</P>
</TD></TR>
<TR><TD valign=top width=84><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=15.733><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=512.267><P style="line-height:13pt; margin:0pt; font-size:11pt">being furnished pursuant to Item 2.02 of Form 8-K.</P>
</TD></TR>
</TABLE>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR></P>
<TABLE style="font-size:10pt" cellspacing=0><TR><TD width=473.4></TD></TR>
<TR><TD valign=top width=631.2><P style="line-height:13pt; margin:0pt; font-size:11pt" align=center>SIGNATURES</P>
</TD></TR>
<TR><TD valign=top width=631.2><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=631.2><P style="line-height:13pt; margin:0pt; font-size:11pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly</P>
</TD></TR>
<TR><TD valign=top width=631.2><P style="line-height:13pt; margin:0pt; font-size:11pt">caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>
</TD></TR>
</TABLE>
<P style="margin:0pt"><BR></P>
<TABLE style="font-size:10pt" cellspacing=0 align=center><TR><TD width=137.7></TD><TD width=189></TD></TR>
<TR><TD valign=top width=183.6><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=252><P style="line-height:13pt; margin:0pt; font-size:11pt">BIO-RAD LABORATORIES, INC.</P>
</TD></TR>
<TR><TD valign=top width=183.6><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=252><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=183.6><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=252><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=183.6><P style="line-height:13pt; margin:0pt; font-size:11pt">Date: &nbsp;<U>November 2, 2006</U></P>
</TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=252><P style="line-height:13pt; margin:0pt; font-size:11pt">/s/ Christine A. Tsingos</P>
</TD></TR>
<TR><TD valign=top width=183.6><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=252><P style="line-height:13pt; margin:0pt; font-size:11pt">Christine A. Tsingos </P>
</TD></TR>
<TR><TD valign=top width=183.6><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=252><P style="line-height:13pt; margin:0pt; font-size:11pt">Vice President and</P>
</TD></TR>
<TR><TD valign=top width=183.6><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=252><P style="line-height:13pt; margin:0pt; font-size:11pt">&nbsp;&nbsp;Chief Financial Officer</P>
</TD></TR>
</TABLE>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR></P>
<TABLE style="font-size:10pt" cellspacing=0><TR><TD width=63></TD><TD width=11.8></TD><TD width=384.2></TD></TR>
<TR><TD valign=top width=612 colspan=3><P style="line-height:13pt; margin:0pt; font-size:11pt" align=center>EXHIBIT INDEX</P>
</TD></TR>
<TR><TD valign=top width=84><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=15.733><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=512.267><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=84><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=15.733><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=512.267><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=84><P style="line-height:13pt; margin:0pt; font-size:11pt">Exhibit </P>
</TD><TD valign=top width=15.733><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=512.267><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD style="border-bottom:0.5pt solid #000000" valign=top width=84><P style="line-height:13pt; margin:0pt; font-size:11pt">Number</P>
</TD><TD valign=top width=15.733><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=512.267><P style="line-height:13pt; margin:0pt; font-size:11pt">Description</P>
</TD></TR>
<TR><TD valign=top width=84><P style="line-height:13pt; margin:0pt; font-size:11pt">99.1</P>
</TD><TD valign=top width=15.733><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=512.267><P style="line-height:13pt; margin:0pt; font-size:11pt">Press Release for third quarter 2006 financial results of</P>
</TD></TR>
<TR><TD valign=top width=84><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=15.733><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=512.267><P style="line-height:13pt; margin:0pt; font-size:11pt">Bio-Rad Laboratories, Inc., dated November 2, 2006. &nbsp;This exhibit is</P>
</TD></TR>
<TR><TD valign=top width=84><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=15.733><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=512.267><P style="line-height:13pt; margin:0pt; font-size:11pt">being furnished pursuant to Item 2.02 of Form 8-K.</P>
</TD></TR>
</TABLE>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR>
<BR></P>
</DIV></BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1 CHARTER
<SEQUENCE>2
<FILENAME>exh991.htm
<TEXT>
<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>
<HEAD>
<TITLE>PART 1 &#8211; FINANCIAL INFORMATION</TITLE>
<META NAME="author" CONTENT="Stephanie Trudrung">
<META NAME="date" CONTENT="11/02/2006">
</HEAD>
<BODY style="line-height:12pt; font-family:Times New Roman; font-size:10pt; color:#000000">
<DIV style="width:453.6pt"><P style="line-height:14pt; margin:0pt; font-size:12pt" align=right><B><U>Exhibit 99.1</U></B></P>
<P style="margin:0pt" align=right><BR></P>
<P style="line-height:11pt; margin:0pt; padding-right:32.4pt; font-family:Arial; font-size:9pt"><FONT FACE="Arial"><B><I>FOR IMMEDIATE RELEASE</I></B></FONT></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR></P>
<P style="line-height:14pt; margin:0pt; font-family:HelveticaNeueLT Std; font-size:12pt" align=center><FONT FACE="HelveticaNeueLT Std"><B>BIO-RAD LABORATORIES REPORTS THIRD-QUARTER RESULTS</B></FONT></P>
<P style="margin:0pt" align=justify><BR></P>
<P style="margin:0pt" align=justify><BR></P>
<P style="line-height:17pt; margin:0pt; font-family:HelveticaNeueLT Std"><B>HERCULES, CA &#150; November 2, 2006 &#150;</B> Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostics products, announced financial results today for the third quarter ended September 30, 2006.<FONT COLOR=#0000FF> </FONT>Third-quarter revenues from continuing operations were $304.8 million, up 7.6% compared to<FONT COLOR=#0000FF> </FONT>$283.2 million reported for the<FONT COLOR=#0000FF> </FONT>third quarter of 2005.<FONT COLOR=#0000FF> </FONT>On a currency-neutral basis, revenues increased 5.1% compared to the same period last year<FONT COLOR=#0000FF>. </FONT>This growth was driven by solid sales across product areas in both the Life Science and Clinical Diagnostics segments. Third-quarter<FONT COLOR=#0000FF> </FONT>income from continuing operations was $23.2 million<FONT COLOR=#0000FF> </FONT>compared to $16.2 million during the third quarter 
last year. The increase in net income included a pre-tax investment gain of $4.7 million realized during the quarter. Third-quarter gross margin from continuing operations was 54.7% compared to 55.4% in the same period last year. </P>
<P style="line-height:17pt; margin:0pt; font-family:HelveticaNeueLT Std">&nbsp;</P>
<P style="line-height:17pt; margin:0pt; font-family:HelveticaNeueLT Std">Year-to-date revenues from continuing operations<FONT COLOR=#0000FF> </FONT>grew by<FONT COLOR=#0000FF> </FONT>6.5% to $930.8 million compared to the first nine months of 2005. Normalizing for the impact of currency effects, year-to-date growth was 7.7%. Income from continuing operations increased by 35.1% to $86.6 million, or $3.29 per share compared to $64.1 million, or $2.47 per share,<B> </B>in the same period last year. Year-to-date gross margin was 56.6% compared to 55.4% for the first nine months of 2005. </P>
<P style="line-height:17pt; margin:0pt; font-family:HelveticaNeueLT Std">&nbsp;</P>
<P style="line-height:16pt; margin:0pt; font-family:HelveticaNeueLT Std"><B>Third-Quarter Highlights</B></P>
<TABLE style="font-size:10pt" cellspacing=0><TR><TD width=18></TD><TD width=450></TD></TR>
<TR><TD valign=top width=24><P style="line-height:16pt; margin:0pt; font-family:Symbol"><FONT FACE="Symbol">&#183;</FONT></P>
</TD><TD valign=top width=600><P style="line-height:16pt; margin:0pt; font-family:HelveticaNeueLT Std"><FONT FACE="HelveticaNeueLT Std">Third-quarter basic earnings from continuing operations were $0.88 per share, or $0.86 per share </FONT></P>
</TD></TR>
<TR><TD valign=top width=24><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=600><P style="line-height:16pt; margin:0pt; font-family:HelveticaNeueLT Std">on a diluted basis, compared to $0.62 and $0.61, respectively, during the same period</P>
</TD></TR>
<TR><TD valign=top width=24><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=600><P style="line-height:16pt; margin:0pt; font-family:HelveticaNeueLT Std">of last year.</P>
</TD></TR>
<TR><TD valign=top width=24><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=600><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=24><P style="line-height:16pt; margin:0pt; font-family:Symbol"><FONT FACE="Symbol">&#183;</FONT></P>
</TD><TD valign=top width=600><P style="line-height:16pt; margin:0pt; font-family:HelveticaNeueLT Std"><FONT FACE="HelveticaNeueLT Std">The Life Science segment reported sales of $137.4 million, a 4.0% increase over the same period </FONT></P>
</TD></TR>
<TR><TD valign=top width=24><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=600><P style="line-height:16pt; margin:0pt; font-family:HelveticaNeueLT Std">last year of $132.1 million. On a currency-neutral basis, segment sales increased 2.0%. &nbsp;</P>
</TD></TR>
<TR><TD valign=top width=24><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=600><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=24><P style="line-height:16pt; margin:0pt; font-family:Symbol"><FONT FACE="Symbol">&#183;</FONT></P>
</TD><TD valign=top width=600><P style="line-height:16pt; margin:0pt; font-family:HelveticaNeueLT Std"><FONT FACE="HelveticaNeueLT Std">Clinical Diagnostics segment net sales for the quarter were $164.4 million, a 10.8% increase over </FONT></P>
</TD></TR>
<TR><TD valign=top width=24><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=600><P style="line-height:16pt; margin:0pt; font-family:HelveticaNeueLT Std">the same period last year of $148.3 million. On a currency-neutral basis, segment sales in this </P>
</TD></TR>
<TR><TD valign=top width=24><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=600><P style="line-height:16pt; margin:0pt; font-family:HelveticaNeueLT Std">area increased by 7.8% compared to the same period last year.</P>
</TD></TR>
<TR><TD valign=top width=24><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=600><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=24><P style="line-height:16pt; margin:0pt; font-family:Symbol"><FONT FACE="Symbol">&#183;</FONT></P>
</TD><TD valign=top width=600><P style="line-height:16pt; margin:0pt; font-family:HelveticaNeueLT Std"><FONT FACE="HelveticaNeueLT Std">In August, Bio-Rad announced that it had signed a definitive agreement to acquire Ciphergen</FONT></P>
</TD></TR>
<TR><TD valign=top width=24><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=600><P style="line-height:16pt; margin:0pt; font-family:HelveticaNeueLT Std">Biosystems, Inc.&#146;s life science business including worldwide technology rights to Ciphergen&#146;s </P>
</TD></TR>
<TR><TD valign=top width=24><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=600><P style="line-height:16pt; margin:0pt; font-family:HelveticaNeueLT Std">Surface Enhanced Laser Desorption/Ionization (SELDI-TOF-MS) technology and</P>
</TD></TR>
<TR><TD valign=top width=24><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=600><P style="line-height:16pt; margin:0pt; font-family:HelveticaNeueLT Std">ProteinChip<SUP>&#174;</SUP> System.</P>
</TD></TR>
</TABLE>
<P style="line-height:16pt; margin:0pt"><BR></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR>
<BR></P>
<P style="margin:0pt; font-family:HelveticaNeueLT Std; page-break-before:always" align=center>(more)</P>
<P style="margin:0pt; font-family:HelveticaNeueLT Std"><B><I>Bio-Rad Reports Third-Quarter Results</I></B></P>
<P style="line-height:17pt; margin:0pt; font-family:HelveticaNeueLT Std"><B><I>Page 2</I></B></P>
<P style="margin:0pt"><BR></P>
<TABLE style="font-size:10pt" cellspacing=0><TR><TD width=22.75></TD><TD width=436.25></TD></TR>
<TR><TD valign=top width=30.333><P style="line-height:16pt; margin:0pt; font-family:Symbol"><FONT FACE="Symbol">&#183;</FONT></P>
</TD><TD valign=top width=581.667><P style="line-height:16pt; margin:0pt; font-family:HelveticaNeueLT Std"><FONT FACE="HelveticaNeueLT Std">During September, Bio-Rad announced the availability of the ProteOn&#8482; XPR36 Protein </FONT></P>
</TD></TR>
<TR><TD valign=top width=30.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=581.667><P style="line-height:16pt; margin:0pt; font-family:HelveticaNeueLT Std">Interaction Array System.</P>
</TD></TR>
<TR><TD valign=top width=30.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=581.667><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=30.333><P style="line-height:16pt; margin:0pt; font-family:Symbol"><FONT FACE="Symbol">&#183;</FONT></P>
</TD><TD valign=top width=581.667><P style="line-height:16pt; margin:0pt; font-family:HelveticaNeueLT Std"><FONT FACE="HelveticaNeueLT Std">In July, Bio-Rad and Integrated DNA Technologies, Inc. entered into a collaboration to develop</FONT></P>
</TD></TR>
<TR><TD valign=top width=30.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=581.667><P style="line-height:16pt; margin:0pt; font-family:HelveticaNeueLT Std">validated RNA interference (RNAi) reagents for life science researchers.</P>
</TD></TR>
</TABLE>
<P style="line-height:16pt; margin:0pt" align=justify><BR></P>
<P style="line-height:17pt; margin:0pt; padding-left:18pt; font-family:HelveticaNeueLT Std">Life Science segment net sales for the quarter were $137.4 million, up 4.0% compared to $132.1 million in the third quarter last year. On a currency-neutral basis, sales increased by 2.0%.<FONT COLOR=#0000FF> </FONT>Performance in this segment was the result of a number of factors<FONT COLOR=#0000FF> </FONT>including first deliveries of the ProteOn XPR36 Protein Interaction Array System. The new instrument provides researchers studying proteins with the ability to capture richer and more comparable data and run more experiments in a shorter period of time. Sales of amplification reagents<FONT COLOR=#0000FF> </FONT>and<FONT COLOR=#0000FF> </FONT>process chromatography media also continued to show growth worldwide. Segment results were somewhat tempered by the continued erosion of BSE testing revenue.<FONT COLOR=#0000FF> &nbsp;</FONT>In July, Bio-Rad and Integrated DNA Technologies, Inc. entered into a collaboration to 
develop validated RNA interference (RNAi) reagents for life science researchers. &nbsp;&nbsp;</P>
<P style="margin:0pt"><BR></P>
<P style="line-height:17pt; margin:0pt; padding-left:18pt; font-family:HelveticaNeueLT Std">The Clinical Diagnostics segment reported sales of $164.4 million, a 10.8% increase over the same period last year of $148.3 million. On a currency-neutral basis, segment sales increased 7.8%. These results are due to continued growth across all product lines especially in the blood virus and quality control product areas. In September, the Company announced that it had completed the purchase of the diagnostics business of Provalis plc, a UK-based provider of point of care diagnostic products for chronic disease management of diabetes and osteoporosis. This acquisition expands Bio-Rad&#146;s market breadth in the area of diabetes monitoring. </P>
<P style="margin:0pt"><BR></P>
<P style="line-height:17pt; margin:0pt; padding-left:18pt; font-family:HelveticaNeueLT Std">In August, Bio-Rad announced that it had signed a definitive agreement to acquire Ciphergen Biosystems, Inc.&#146;s life science business including worldwide technology rights to Ciphergen&#146;s Surface Enhanced Laser Desorption/Ionization (SELDI-TOF-MS) technology and ProteinChip System. The acquisition, which is in the process of being completed, provides Bio-Rad with access to leading protein analysis technology for the life science market and represents a significant addition to the Company&#146;s portfolio of products. </P>
<P style="line-height:16pt; margin:0pt" align=center><BR></P>
<P style="line-height:16pt; margin:0pt" align=center><BR></P>
<P style="line-height:16pt; margin:0pt" align=center><BR></P>
<P style="line-height:16pt; margin:0pt" align=justify><BR></P>
<P style="line-height:16pt; margin:0pt" align=center><BR></P>
<P style="line-height:16pt; margin:0pt" align=center><BR></P>
<P style="line-height:16pt; margin:0pt" align=center><BR></P>
<P style="line-height:16pt; margin:0pt" align=center><BR></P>
<P style="line-height:16pt; margin:0pt" align=center><BR></P>
<P style="line-height:16pt; margin:0pt; font-family:HelveticaNeueLT Std; page-break-before:always" align=center>(more)</P>
<P style="margin:0pt; font-family:HelveticaNeueLT Std"><B><I>Bio-Rad Reports Third-Quarter Results</I></B></P>
<P style="margin:0pt; font-family:HelveticaNeueLT Std"><B><I>Page 3</I></B></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR></P>
<P style="line-height:17pt; margin:0pt; font-family:HelveticaNeueLT Std">&#147;Overall, we are pleased with the company&#146;s performance in the third quarter,&#148; said Norman Schwartz, Bio-Rad President and Chief Executive Officer. &#147;Sales are meeting or exceeding expectations and new products are finding acceptance around the world.<B>&#148;</B></P>
<P style="margin:0pt"><BR></P>
<P style="line-height:17pt; margin:0pt; font-family:HelveticaNeueLT Std">Management will discuss these results in a conference call at 2 p.m. Pacific Standard Time (5 p.m. Eastern Standard Time) November 2, 2006.<FONT COLOR=#0000FF> </FONT>Interested parties can access the call by dialing 866-543-6411 (in the U.S.), or<FONT COLOR=#0000FF> </FONT>617-213-8900 (international),<FONT COLOR=#0000FF> </FONT>access number 91475971.<FONT COLOR=#0000FF> </FONT>The live webcast can be accessed at <U>http://www.bio-rad.com</U>. A replay of the call will be available at<FONT COLOR=#0000FF> </FONT>888-286-8010 (in the U.S.), or 617-801-6888 (international), access number 39220678, for seven days following the call and the webcast can be accessed at <U>http://www.bio-rad.com</U> for 30 days.</P>
<P style="margin:0pt"><BR></P>
<P style="line-height:17pt; margin:0pt; font-family:HelveticaNeueLT Std"><B>About Bio-Rad</B></P>
<P style="line-height:17pt; margin:0pt; font-family:HelveticaNeueLT Std">Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb), has remained at the center of scientific discovery for more than 50 years manufacturing and distributing a broad range of products for the life science research and clinical diagnostics markets. The company is renowned worldwide among hospitals, universities, major research institutions as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 5,000 people globally and had revenues of $1.1 billion in 2005. For more information, please visit </P>
<P style="line-height:17pt; margin:0pt; font-family:HelveticaNeueLT Std">www.bio-rad.com. </P>
<P style="margin:0pt"><BR></P>
<P style="line-height:11pt; margin:0pt; font-family:HelveticaNeueLT Std; font-size:9pt"><I>Various statements made within this press release may constitute &#147;forward-looking statements&#148; for purposes of the Securities and Exchange Commission&#146;s &#147;safe harbor&#148; provisions under the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934. The forward-looking statements contained herein involve risks and uncertainties that could cause results to differ materially from the Company&#146;s expectations.</I></P>
<P style="margin:0pt" align=justify><BR></P>
<P style="line-height:16pt; margin:0pt; font-family:HelveticaNeueLT Std"><B>For more information contact:</B></P>
<P style="line-height:16pt; margin:0pt; font-family:HelveticaNeueLT Std">Christine Tsingos, Vice President and Chief Financial Officer, or</P>
<P style="line-height:16pt; margin:0pt; font-family:HelveticaNeueLT Std">Ron Hutton, Treasurer</P>
<P style="line-height:16pt; margin:0pt; font-family:HelveticaNeueLT Std">Bio-Rad Laboratories, Inc.</P>
<P style="line-height:16pt; margin:0pt; font-family:HelveticaNeueLT Std">510-724-7000</P>
<P style="line-height:16pt; margin:0pt; font-family:HelveticaNeueLT Std">investor_relations@bio-rad.com</P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR>
<BR></P>
<P style="margin:0pt; page-break-before:always"><BR></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt" align=right><BR></P>
<TABLE style="font-size:10pt" cellspacing=0><TR><TD width=239.5></TD><TD width=55.9></TD><TD width=9></TD><TD width=53.75></TD><TD width=9></TD><TD width=58.25></TD><TD width=9.25></TD><TD width=53.25></TD></TR>
<TR><TD valign=top width=650.533 colspan=8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=650.533 colspan=8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=650.533 colspan=8><P style="line-height:11pt; margin:0pt; font-size:9pt" align=center><FONT FACE="Times New Roman">BIO-RAD LABORATORIES, INC.</FONT></P>
</TD></TR>
<TR><TD valign=top width=650.533 colspan=8><P style="line-height:11pt; margin:0pt; font-size:9pt" align=center>Condensed Consolidated Statements of Income</P>
</TD></TR>
<TR><TD valign=top width=650.533 colspan=8><P style="line-height:11pt; margin:0pt; font-size:9pt" align=center>(In thousands, except per share data)</P>
</TD></TR>
<TR><TD valign=top width=650.533 colspan=8><P style="line-height:11pt; margin:0pt; font-size:9pt" align=center>(Unaudited)</P>
</TD></TR>
<TR><TD valign=top width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=158.2 colspan=3><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=12><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=161 colspan=3><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=158.2 colspan=3><P style="line-height:11pt; margin:0pt; font-size:9pt" align=center>Three Months Ended</P>
<P style="line-height:11pt; margin:0pt; font-size:9pt" align=center>September 30,</P>
</TD><TD valign=top width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=161 colspan=3><P style="line-height:11pt; margin:0pt; font-size:9pt" align=center>Nine Months Ended</P>
<P style="line-height:11pt; margin:0pt; font-size:9pt" align=center>September 30,</P>
</TD></TR>
<TR><TD width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=center>2006</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=center>2005</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=center>2006</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=center>2005</P>
</TD></TR>
<TR><TD width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=74.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; font-size:9pt">Net sales</P>
</TD><TD width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;304,764&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;283,225&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;930,849&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;873,698&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; text-indent:14.4pt; font-size:9pt">Cost of goods sold</P>
</TD><TD style="border-bottom:0.5pt solid #000000" width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>137,975&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>126,413&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>403,870&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>389,837&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; font-size:9pt">Gross profit</P>
</TD><TD width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>166,789&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>156,812&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>526,979&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>483,861&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; font-size:9pt">Selling, general and administrative expense</P>
</TD><TD width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>105,950&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>102,738&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>316,486&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>306,458&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; font-size:9pt">Product research and development expense</P>
</TD><TD width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>30,988&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>28,673&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>90,050&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>83,995&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; font-size:9pt">Interest expense</P>
</TD><TD width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>8,212&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>8,210&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>24,111&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>24,371&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; font-size:9pt">Foreign exchange (gains) losses, net</P>
</TD><TD width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>(293)</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>(97)</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>959&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>(1,296)</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; font-size:9pt">Other (income) expense, net</P>
</TD><TD width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>(10,514)</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>(3,506)</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>(22,809)</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>(14,033)</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; font-size:9pt">Income from continuing operations before taxes</P>
</TD><TD style="border-top:0.5pt solid #000000" width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>32,446&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>20,794&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>118,182&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>84,366&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; text-indent:14.4pt; font-size:9pt">Provision for income taxes</P>
</TD><TD style="border-bottom:0.5pt solid #000000" width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>9,296&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>4.575&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>31,568&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>20,239&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; font-size:9pt">Income from continuing operations</P>
</TD><TD width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>23,150&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>16,219&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>86,614&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>64,127&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; font-size:9pt">Discontinued operations</P>
</TD><TD width=74.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; text-indent:14.4pt; font-size:9pt">Gain on divestiture, net of tax benefits of zero in 2005</P>
</TD><TD style="border-bottom:0.5pt solid #000000" width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>--&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>--&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>--&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>3,974&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; font-size:9pt">Net income</P>
</TD><TD style="border-bottom:2pt double #000000" width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;23,150&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;16,219&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;86,614&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;68,101&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=74.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; font-size:9pt">Basic earnings per share:</P>
</TD><TD width=74.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; text-indent:14.4pt; font-size:9pt">Continuing operations</P>
</TD><TD width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;0.88</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;0.62&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;3.29</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;2.47&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; text-indent:14.4pt; font-size:9pt">Discontinued operations</P>
</TD><TD style="border-bottom:0.5pt solid #000000" width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>--</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>--&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>--</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>0.15&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; text-indent:14.4pt; font-size:9pt">Net income</P>
</TD><TD style="border-bottom:2pt double #000000" width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;0.88</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;0.62&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;3.29</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;2.62&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; text-indent:14.4pt; font-size:9pt">Weighted average common shares</P>
</TD><TD style="border-bottom:2pt double #000000" width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>26,407&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>26,115&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>26,342&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>26,015&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=74.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; font-size:9pt">Diluted earnings per share:</P>
</TD><TD width=74.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; text-indent:14.4pt; font-size:9pt">Continuing operations</P>
</TD><TD width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;0.86&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;0.61&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;3.22&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;2.41&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; text-indent:14.4pt; font-size:9pt">Discontinued operations</P>
</TD><TD style="border-bottom:0.5pt solid #000000" width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>--&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>--&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>--&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>0.15&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; text-indent:14.4pt; font-size:9pt">Net income</P>
</TD><TD style="border-bottom:2pt double #000000" width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;0.86&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;0.61&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;3.22&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;2.56&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; text-indent:14.4pt; font-size:9pt">Weighted average common shares</P>
</TD><TD style="border-bottom:2pt double #000000" width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>26,971&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>26,695&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>26,900&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>26,620&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=74.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=74.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="font-size:2pt">&nbsp;</P></TD></TR>
</TABLE>
<P style="margin:0pt" align=center><BR>
<BR></P>
<P style="margin:0pt; padding-left:-36pt; padding-right:-49pt; font-size:9pt; page-break-before:always" align=center>BIO-RAD LABORATORIES, INC</P>
<P style="margin:0pt; font-size:9pt" align=center>Condensed Consolidated Balance Sheets</P>
<P style="margin:0pt; font-size:9pt" align=center>(In thousands)</P>
<P style="margin:0pt; font-size:9pt" align=center>(Unaudited)</P>
<TABLE style="font-size:10pt" cellspacing=0><TR><TD width=311.75></TD><TD width=12.5></TD><TD width=70.15></TD><TD width=12.5></TD><TD width=66.5></TD></TR>
<TR><TD width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=93.533><P style="line-height:9pt; margin:0pt; font-size:9pt" align=center>September 30,</P>
<P style="line-height:9pt; margin:0pt; font-size:9pt" align=center>2006</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=88.667><P style="line-height:9pt; margin:0pt; font-size:9pt" align=center>December 31, 2005</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0pt; font-size:9pt">Current assets: </P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=93.533><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=88.667><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0pt; padding-left:14.4pt; font-size:9pt">Cash and cash equivalents &nbsp;</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=93.533><P style="margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;238,418&nbsp;</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=88.667><P style="margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;296,716&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0pt; padding-left:14.4pt; font-size:9pt">Restricted cash</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=93.533><P style="margin:0pt; font-size:9pt" align=right>--&nbsp;</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=88.667><P style="margin:0pt; font-size:9pt" align=right>36,138&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0pt; padding-left:14.4pt; font-size:9pt">Short-term investments</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=93.533><P style="margin:0pt; font-size:9pt" align=right>243,155&nbsp;</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=88.667><P style="margin:0pt; font-size:9pt" align=right>116,343&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0pt; padding-left:14.4pt; font-size:9pt">Accounts receivable, net </P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=93.533><P style="margin:0pt; font-size:9pt" align=right>273,367&nbsp;</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=88.667><P style="margin:0pt; font-size:9pt" align=right>247,192&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0pt; padding-left:14.4pt; font-size:9pt">Inventories, net </P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=93.533><P style="margin:0pt; font-size:9pt" align=right>246,207&nbsp;</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=88.667><P style="margin:0pt; font-size:9pt" align=right>212,342&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0pt; padding-left:14.4pt; font-size:9pt">Other current assets</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=93.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>91,566&nbsp;</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=88.667><P style="margin:0pt; font-size:9pt" align=right>99,480&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0pt; text-indent:21.6pt; font-size:9pt">Total current assets </P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=93.533><P style="margin:0pt; font-size:9pt" align=right>1,092,713&nbsp;</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=88.667><P style="margin:0pt; font-size:9pt" align=right>1,008,211&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0pt; font-size:9pt">Net property, plant and equipment </P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=93.533><P style="margin:0pt; font-size:9pt" align=right>182,728&nbsp;</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=88.667><P style="margin:0pt; font-size:9pt" align=right>180,258&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0pt; font-size:9pt">Goodwill </P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=93.533><P style="margin:0pt; font-size:9pt" align=right>113,276&nbsp;</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=88.667><P style="margin:0pt; font-size:9pt" align=right>113,276&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0pt; font-size:9pt">Purchased intangibles, net</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=93.533><P style="margin:0pt; font-size:9pt" align=right>24,926&nbsp;</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=88.667><P style="margin:0pt; font-size:9pt" align=right>28,449&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0pt; font-size:9pt">Other assets </P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=93.533><P style="margin:0pt; font-size:9pt" align=right>109,992&nbsp;</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=88.667><P style="margin:0pt; font-size:9pt" align=right>96,388&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0pt; text-indent:21.6pt; font-size:9pt">Total assets</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=93.533><P style="margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1,523,635&nbsp;</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=88.667><P style="margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1,426,582&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=93.533><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=88.667><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0pt; font-size:9pt">Current liabilities:</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=93.533><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=88.667><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0pt; padding-left:14.4pt; font-size:9pt">Notes payable and current maturities of long-term debt</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=93.533><P style="margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3,768&nbsp;</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=88.667><P style="margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3,341&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0pt; padding-left:14.4pt; font-size:9pt">Accounts payable</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=93.533><P style="margin:0pt; font-size:9pt" align=right>64,513&nbsp;</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=88.667><P style="margin:0pt; font-size:9pt" align=right>&nbsp;72,950&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0pt; padding-left:14.4pt; font-size:9pt">Accrued payroll and employee benefits</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=93.533><P style="margin:0pt; font-size:9pt" align=right>79,456&nbsp;</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=88.667><P style="margin:0pt; font-size:9pt" align=right>81,076&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0pt; padding-left:14.4pt; font-size:9pt">Sales, income and other taxes payable</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=93.533><P style="margin:0pt; font-size:9pt" align=right>19,075&nbsp;</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=88.667><P style="margin:0pt; font-size:9pt" align=right>15,841&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0pt; padding-left:14.4pt; font-size:9pt">Other current liabilities</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=93.533><P style="margin:0pt; font-size:9pt" align=right>114,500&nbsp;</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=88.667><P style="margin:0pt; font-size:9pt" align=right>146,035&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0pt; text-indent:21.6pt; font-size:9pt">Total current liabilities</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=93.533><P style="margin:0pt; font-size:9pt" align=right>281,312&nbsp;</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=88.667><P style="margin:0pt; font-size:9pt" align=right>319,243&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=93.533><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=88.667><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0pt; font-size:9pt">Long-term debt, net of current maturities</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=93.533><P style="margin:0pt; font-size:9pt" align=right>425,750&nbsp;</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=88.667><P style="margin:0pt; font-size:9pt" align=right>425,687&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0pt; font-size:9pt">Other long-term liabilities</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=93.533><P style="margin:0pt; font-size:9pt" align=right>31,833&nbsp;</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=88.667><P style="margin:0pt; font-size:9pt" align=right>23,678&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0pt; font-size:9pt">Stockholders&#146; equity</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=93.533><P style="margin:0pt; font-size:9pt" align=right>784,740&nbsp;</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=88.667><P style="margin:0pt; font-size:9pt" align=right>657,974&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0pt; text-indent:28.8pt; font-size:9pt">Total liabilities and stockholders&#146; equity</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=93.533><P style="margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1,523,635&nbsp;</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=88.667><P style="margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1,426,582&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=93.533><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=88.667><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=631.2 colspan=5><P style="font-size:2pt">&nbsp;</P></TD></TR>
</TABLE>
<P style="line-height:11pt; margin-top:0pt; margin-bottom:4.5pt; font-size:9pt">&nbsp;</P>
<P style="margin-top:0pt; margin-bottom:4.5pt"><BR>
<BR></P>
<P style="margin-top:0pt; margin-bottom:4.5pt; page-break-before:always"><BR></P>
<TABLE style="font-size:10pt" cellspacing=0><TR><TD width=284.75></TD><TD width=53.65></TD><TD width=12.5></TD><TD width=50.85></TD></TR>
<TR><TD valign=top width=535.667 colspan=4><P style="line-height:10pt; margin:0pt; font-size:9pt" align=center>BIO-RAD LABORATORIES, INC.</P>
</TD></TR>
<TR><TD valign=top width=535.667 colspan=4><P style="line-height:10pt; margin:0pt; font-size:9pt" align=center>Condensed Consolidated Statements of Cash Flows</P>
</TD></TR>
<TR><TD valign=top width=535.667 colspan=4><P style="line-height:10pt; margin:0pt; font-size:9pt" align=center>(In thousands)</P>
</TD></TR>
<TR><TD valign=top width=535.667 colspan=4><P style="line-height:10pt; margin:0pt; font-size:9pt" align=center>(Unaudited) &nbsp;</P>
</TD></TR>
<TR><TD valign=top width=379.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=71.533><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=67.8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=379.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=156 colspan=3><P style="line-height:10pt; margin:0pt; font-size:9pt" align=center>Nine Months Ended</P>
</TD></TR>
<TR><TD valign=top width=379.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=156 colspan=3><P style="line-height:10pt; margin:0pt; font-size:9pt" align=center>September 30,</P>
</TD></TR>
<TR><TD valign=top width=379.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=71.533><P style="line-height:10pt; margin:0pt; font-size:9pt" align=center>2006</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=67.8><P style="line-height:10pt; margin:0pt; font-size:9pt" align=center>2005</P>
</TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt">Cash flows from operating activities:</P>
</TD><TD width=71.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; padding-left:14.4pt; font-size:9pt">Cash received from customers</P>
</TD><TD width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;915,289&nbsp;</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>$ &nbsp;&nbsp;&nbsp;865,235&nbsp;</P>
</TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; padding-left:14.4pt; font-size:9pt">Cash paid to suppliers and employees</P>
</TD><TD width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>(789,626)</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>(762,788)</P>
</TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; padding-left:14.4pt; font-size:9pt">Interest paid</P>
</TD><TD width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>(24,528)</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>(24,489)</P>
</TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; padding-left:14.4pt; font-size:9pt">Income tax payments</P>
</TD><TD width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>(9,595)</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>(30,085)</P>
</TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; padding-left:14.4pt; font-size:9pt">Litigation settlement related to MJ acquisition</P>
</TD><TD width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>(45,963)</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>--&nbsp;</P>
</TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; padding-left:14.4pt; font-size:9pt">Other operating activities</P>
</TD><TD style="border-bottom:0.5pt solid #000000" width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>17,789&nbsp;</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>11,018&nbsp;</P>
</TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; padding-left:14.4pt; font-size:9pt">Net cash provided by operating activities</P>
</TD><TD width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>63,366&nbsp;</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>58,891&nbsp;</P>
</TD></TR>
<TR><TD width=379.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt">Cash flows from investing activities:</P>
</TD><TD width=71.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; padding-left:14.4pt; font-size:9pt">Capital expenditures, net</P>
</TD><TD width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>(38,079)</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>(26,297)</P>
</TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; padding-left:14.4pt; font-size:9pt">Receipt (payment) of restricted cash</P>
</TD><TD width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>36,138&nbsp;</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>(35,828)</P>
</TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; padding-left:14.4pt; font-size:9pt">Other investing activities </P>
</TD><TD style="border-bottom:0.5pt solid #000000" width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>(132,102)</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>47,830&nbsp;</P>
</TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; padding-left:14.4pt; font-size:9pt">Net cash used in investing activities</P>
</TD><TD width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>(134,043)</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>(14,295)</P>
</TD></TR>
<TR><TD width=379.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt">Cash flows from financing activities:</P>
</TD><TD width=71.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; padding-left:14.4pt; font-size:9pt">Proceeds from issuance of common stock</P>
</TD><TD width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>8,511&nbsp;</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>6,919&nbsp;</P>
</TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; padding-left:14.4pt; font-size:9pt">Other financing activities</P>
</TD><TD style="border-bottom:0.5pt solid #000000" width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>1,051&nbsp;</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>(2,416)</P>
</TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; padding-left:14.4pt; font-size:9pt">Net cash provided by financing activities</P>
</TD><TD width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>9,562&nbsp;</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>4,503&nbsp;</P>
</TD></TR>
<TR><TD width=379.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt">Effect of exchange rate changes on cash</P>
</TD><TD width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>2,817&nbsp;</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>(853)</P>
</TD></TR>
<TR><TD width=379.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt">Net increase (decrease) in cash and cash equivalents</P>
</TD><TD style="border-top:0.5pt solid #000000" width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>(58,298)</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-top:0.5pt solid #000000" width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>48,246&nbsp;</P>
</TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt">Cash and cash equivalents at beginning of period</P>
</TD><TD style="border-bottom:0.5pt solid #000000" width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>296,716&nbsp;</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>195,734&nbsp;</P>
</TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt">Cash and cash equivalents at end of period</P>
</TD><TD style="border-bottom:2pt double #000000" width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;238,418&nbsp;</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>$ &nbsp;&nbsp;&nbsp;243,980&nbsp;</P>
</TD></TR>
<TR><TD width=379.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=451.2 colspan=2><P style="line-height:11pt; margin:0pt; font-size:9pt">Reconciliation of net income to net cash provided by operating activities:</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin:0pt; padding-left:14.4pt; font-size:9pt">Net income </P>
</TD><TD width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>$ &nbsp;&nbsp;&nbsp;86,614&nbsp;</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;68,101&nbsp;</P>
</TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; padding-left:14.4pt; font-size:9pt">Adjustments to reconcile net income to net cash provided by</P>
</TD><TD width=71.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:3.75pt; font-size:9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;operating activities:</P>
</TD><TD width=71.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; padding-left:14.4pt; font-size:9pt">Depreciation and amortization</P>
</TD><TD width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>40,300&nbsp;</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>44,581&nbsp;</P>
</TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; padding-left:14.4pt; font-size:9pt">Changes in working capital</P>
</TD><TD width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>(29,876)</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>(37,674)</P>
</TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; padding-left:14.4pt; font-size:9pt">Litigation settlement related to MJ acquisition</P>
</TD><TD width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>(45,963)</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>--&nbsp;</P>
</TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; padding-left:14.4pt; font-size:9pt">Other</P>
</TD><TD style="border-bottom:0.5pt solid #000000" width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>12,291&nbsp;</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>(16,117)</P>
</TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt">Net cash provided by operating activities</P>
</TD><TD style="border-bottom:2pt double #000000" width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;63,366&nbsp;</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;58,891&nbsp;</P>
</TD></TR>
<TR><TD width=379.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=379.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=451.2 colspan=2><P style="font-size:2pt">&nbsp;</P></TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="font-size:2pt">&nbsp;</P></TD></TR>
</TABLE>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR>
<BR></P>
</DIV></BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
